• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定抗癌药物耐药性小分子抑制剂的方案。

Protocol to identify small-molecule inhibitors against cancer drug resistance.

作者信息

Wei Juan, Zhang She-Yu, Zhou Xue-Yuan, Wei Yong, Jia Hao-Ran, Wu Qin, Tan Weihong

机构信息

School of Science, Tianjin University, Tianjin, China.

School of Life Sciences, Tianjin University, Tianjin, China.

出版信息

STAR Protoc. 2025 Mar 21;6(1):103605. doi: 10.1016/j.xpro.2025.103605. Epub 2025 Jan 30.

DOI:10.1016/j.xpro.2025.103605
PMID:39888719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11821401/
Abstract

Drug resistance has emerged as a critical challenge in clinical cancer treatment. Here, we present a high-throughput screening protocol to identify therapeutic small-molecule inhibitors against drug-resistant cancer cells. We detail the steps for constructing drug-resistant cell models, executing the chemical screening process, and performing data analysis and validation. This protocol facilitates the rapid identification of therapeutic strategies for different types of drug-resistant cancers and aids in studying mechanisms. For complete details on the use and execution of this protocol, please refer to Zhang et al..

摘要

耐药性已成为临床癌症治疗中的一项关键挑战。在此，我们提出一种高通量筛选方案，以鉴定针对耐药癌细胞的治疗性小分子抑制剂。我们详细介绍了构建耐药细胞模型、进行化学筛选过程以及进行数据分析和验证的步骤。该方案有助于快速确定针对不同类型耐药癌症的治疗策略，并有助于研究其机制。有关该方案使用和执行的完整详细信息，请参考Zhang等人的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/8ed626eb96cc/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/2e2d7ef0dcde/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/79dcd59713ce/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/5cc52400babe/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/03cf2293b742/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/4ceff276a5f5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/8ed626eb96cc/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/2e2d7ef0dcde/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/79dcd59713ce/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/5cc52400babe/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/03cf2293b742/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/4ceff276a5f5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4396/11821401/8ed626eb96cc/gr5.jpg

相似文献

1
Protocol to identify small-molecule inhibitors against cancer drug resistance.鉴定抗癌药物耐药性小分子抑制剂的方案。
STAR Protoc. 2025 Mar 21;6(1):103605. doi: 10.1016/j.xpro.2025.103605. Epub 2025 Jan 30.
2
Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay.通过原位抗性测定在贴壁和悬浮癌细胞系中模拟获得性靶向治疗抗性的方案。
STAR Protoc. 2024 Dec 20;5(4):103361. doi: 10.1016/j.xpro.2024.103361. Epub 2024 Oct 5.
3
A protocol for high-throughput screening for small chemicals promoting macrophage-mediated tumor cell phagocytosis in mice.一种用于高通量筛选促进小鼠巨噬细胞介导的肿瘤细胞吞噬作用的小分子化学物质的方案。
STAR Protoc. 2025 Mar 21;6(1):103512. doi: 10.1016/j.xpro.2024.103512. Epub 2024 Dec 18.
4
High-throughput drug screening using a library of antibiotics targeting cancer cell lines that are resistant and sensitive to gemcitabine.使用针对对吉西他滨耐药和敏感的癌细胞系的抗生素文库进行高通量药物筛选。
Biochem Biophys Res Commun. 2024 Oct 20;730:150369. doi: 10.1016/j.bbrc.2024.150369. Epub 2024 Jul 7.
5
Protocol to develop a chemotherapy drug screening process by constructing a cancer prognostic model using public databases.利用公共数据库构建癌症预后模型来开发化疗药物筛选流程的方案。
STAR Protoc. 2024 Sep 20;5(3):103158. doi: 10.1016/j.xpro.2024.103158. Epub 2024 Jun 28.
6
Protocol for generation of and high-throughput drug testing with patient-derived colorectal cancer organoids.患者来源结直肠癌细胞类器官的生成及高通量药物筛选的方案。
STAR Protoc. 2024 Jun 21;5(2):103090. doi: 10.1016/j.xpro.2024.103090. Epub 2024 May 28.
7
Discovery of -Enprioline as a Novel Drug for the Treatment of Vincristine Resistant Neuroblastoma.发现 -Enprioline 是一种治疗长春新碱耐药神经母细胞瘤的新型药物。
Int J Mol Sci. 2020 Sep 8;21(18):6577. doi: 10.3390/ijms21186577.
8
Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens.通过化合物文库筛选鉴定淋巴瘤和白血病细胞的脆弱性和耐药性。
Methods Mol Biol. 2025;2865:259-272. doi: 10.1007/978-1-0716-4188-0_11.
9
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.无偏高效药物组合初步筛选发现有效对抗患者来源和耐药黑素瘤细胞系的协同药物组合。
SLAS Discov. 2021 Jun;26(5):712-729. doi: 10.1177/2472555220970917. Epub 2020 Nov 18.
10
Protocol for long-term treatment of lowly aggressive cancer cell lines with low concentrations of anti-tumor drugs.长期用低浓度抗肿瘤药物治疗低度侵袭性癌细胞系的方案。
STAR Protoc. 2024 Sep 20;5(3):103210. doi: 10.1016/j.xpro.2024.103210. Epub 2024 Jul 13.

本文引用的文献

1
A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.一种化学筛选方法确定 PRMT5 是紫杉醇耐药性三阴性乳腺癌的治疗弱点。
Cell Chem Biol. 2024 Nov 21;31(11):1942-1957.e6. doi: 10.1016/j.chembiol.2024.08.003. Epub 2024 Sep 3.
2
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.伊帕替膦联合阿替利珠单抗和紫杉烷类三药方案治疗转移性三阴性乳腺癌的临床和生物标志物结果。
Clin Cancer Res. 2024 Feb 16;30(4):767-778. doi: 10.1158/1078-0432.CCR-23-2084.
3
Alteration of chromatin high-order conformation associated with oxaliplatin resistance acquisition in colorectal cancer cells.
与大肠癌细胞中获得性奥沙利铂耐药相关的染色质高级构象改变
Exploration (Beijing). 2023 May 29;3(4):20220136. doi: 10.1002/EXP.20220136. eCollection 2023 Aug.
4
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.哺乳动物 SWI/SNF 染色质重塑复合物促进 EGFR 突变型肺癌对酪氨酸激酶抑制剂的耐药性。
Cancer Cell. 2023 Aug 14;41(8):1516-1534.e9. doi: 10.1016/j.ccell.2023.07.005. Epub 2023 Aug 3.
5
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.线粒体适应性在癌症耐药中的作用：普遍性、机制与管理。
J Hematol Oncol. 2022 Jul 18;15(1):97. doi: 10.1186/s13045-022-01313-4.
6
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.PRMT 抑制在三阴性乳腺癌中诱导病毒模拟反应。
Nat Chem Biol. 2022 Aug;18(8):821-830. doi: 10.1038/s41589-022-01024-4. Epub 2022 May 16.
7
Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.紫杉醇对乳腺癌的作用机制和临床疗效。
Biomolecules. 2019 Nov 27;9(12):789. doi: 10.3390/biom9120789.